Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

By S. Lakhani, J. Reis-Filho, L. Fulford, F. Penault-Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benítez, C. Rivas, Y. Bignon and 26 more. Clinical Cancer Research, 2005

669 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/59e46f8e29c9649a5e6bbe6066999751326f3f36

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Reis-Filho
2. Olivier Elemento
3. Alan Ashworth
4. M. J. van de Vijver
5. Lisa A. Carey
6. Andrew Tutt
7. Jane E. Visvader

In Genetics

1. Jane E. Visvader
2. Alan Ashworth
3. J. Reis-Filho
4. Andrew Tutt
5. Olivier Elemento
6. N. Turner
7. L. Gianni

Citations in the corpus

• Triple-negative breast cancer--current status and future directions. (2009, background): “Additional characteristics of BLBC are frequent metaplastic elements and medullary/atypical medullary features [28,29,34,35].”
• BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010, background): “Strikingly, the majority of breast tumors arising in carriers of germline mutations in BRCA1 have the basal-like phenotype (Lakhani et al., 2005; Palacios et al., 2005).”
• BRCA1 dysfunction in sporadic basal-like breast cancer (2007, background): “We hypothesized that the phenotypic overlap of BRCA1 familial cancers and sporadic basal-like cancers (Foulkes et al., 2003; Sorlie et al., 2003; Lakhani et al., 2005) implied that sporadic basal-like cancers might have an underlying defect in BRCA1-related pathways (Turner et al., 2004).”
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007, background): “Specific subgroups of triple-negative tumors may be formed by medullary and atypical medullary cancers [12,37-39].”
• Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images (2017, background): “Furthermore, the minimum mis-classification is related to the score 3 and EGFR marker which is a well known basal marker for breast cancer therapy (Lakhani et al., 2005).”
• Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “TNBC and the BRCA1 pathway The majority of tumors in BRCA1 mutation carriers are triple negative and show morphological and immunohistochemical similarities to BLBCs”
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene (2010, background): “Despite the fact that five of the seven ovarian cancers presented as pT3 tumors, only two had lymph node involvement, again indicating distinct features compared to BRCA1 -associated ovarian cancers, the majority of which are poorly differentiated invasive serous adenocarcinoma”
• Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. (2009, background): “However, ERa is expressed on about one-third of luminal progenitor cells; furthermore, not all BRCA1 tumors are negative for ERa, with up to 30% expressing variable levels of this receptor (Lakhani et al. 2005).”